Comparative PSMA PET Tracer Performance in Advanced Prostate Cancer

In this episode, ‘Comparative PSMA PET Tracer Performance in Advanced Prostate Cancer,’ Dr. Neal Shore explores the clinical relevance of emerging phase 4 data comparing urinary radioactivity and detection rates among PSMA PET tracers in advanced prostate cancer. In patients with low prostate-specific antigen (PSA) biochemical recurrence, excessive urinary excretion of certain tracers can obscure visualization of the prostate bed and surrounding tissues, making it more difficult to detect local recurrence. As a result, differences in tracer biodistribution, particularly urinary bladder activity, have meaningful implications for diagnostic accuracy in these settings.

The discussion emphasizes findings from a recent ASCO GU presentation demonstrating notable differences in detection rates between fluorinated PSMA PET agents, with one tracer showing substantially higher lesion detection, including in the prostate bed and pelvic lymph nodes. These results suggest that reduced urinary radioactivity may improve visualization of clinically relevant disease, particularly in post-prostatectomy or post-radiation patients. This represents one of the first intra-patient comparative analyses, offering more direct evidence than prior cross-trial comparisons.

Beyond imaging performance, clinicians also consider factors such as availability, regulatory approval, and economic considerations when selecting among PSMA PET tracers. While these practical elements vary globally and across healthcare systems, the discussion underscores that diagnostic performance, sensitivity, specificity, and detection capability, remains a key driver of treatment decisions. Overall, this segment highlights how emerging comparative data may begin to influence tracer selection and refine imaging strategies in advanced prostate cancer.

The next episode in this series, ‘Integrating PSMA PET into Clinical Practice in Advanced Prostate Cancer,’ features Dr. Neal Shore discussing the growing role of PSMA PET as a standard imaging tool in advanced prostate cancer and its integration into clinical practice. Accurate interpretation and multidisciplinary collaboration are essential to maximizing its impact on patient care.